Session Detail


Session Number: 99
Session Title: The Global Program to Eliminate Lymphatic Filariasis: Where Are We Now?
Session Type: Symposium
Session Start/End Time: Friday, Nov 15, 2013, 1:45 PM - 3:30 PM
Location: Lincoln 3/4
Session Description: When the World Health Organization’s Global Programme to Eliminate Lymphatic Filariasis (GPELF) was established in 2000, targeting both interruption of transmission and management of LF-related morbidity, 1.2 billion people were estimated to be at risk of infection in 83 countries with 120 million already affected, including the 40 million suffering from hydrocele or lymphedema. To date, over 50 countries have implemented mass drug administration against LF, many for the recommended five or more years. Consequently, the number of people at risk of infection and those affected have decreased significantly since programs began 13 years ago. Further, recent studies have demonstrated that mass drug administration goes beyond just preventing transmission to actually preventing progression from subclinical to clinical disease and, in less severe cases, may even reverse lymphatic damage to resolve morbidity. Important progress has also been made at the policy level, ensuring that vital program guidelines are in place to support endemic countries’ elimination efforts. This symposium will present current methods used to assess the impact of the GPELF in decreasing both the burden of LF disease and the number of those currently at risk of infection (by close to 50%). It will also identify the policy implications in order for the GPELF to reach its 2020 elimination and disease management targets.
Presentations:
Symposium Organizer
Eric A. Ottesen
NTD Support Center, Task Force for Global Health, Decatur, GA, United States

Co-Chair
Charles D. Mackenzie
Pathobiology and Diagnostic Investigation, Michigan State University, East Lansing, MI, United States

11/15/2013 1:45:00 PM
The Global Programme to Eliminate LF: 13 years of progress in decreasing those living at-risk of LF disease
Mark Bradley
GlaxoSmithKline, Brentford, United Kingdom

11/15/2013 2:05:00 PM
An updated look at the decrease in the global burden of lymphatic filariasis disease
Kapa Ramaiah
Consultant, Pondicherry, India

11/15/2013 2:25:00 PM
Lymphatic filariasis morbidity management and disability prevention – Getting the numbers right
Vasanthapuram Kumaraswami
Consultant, Chennai, India

11/15/2013 2:45:00 PM
Creating the Policy Context for the Elimination of LF
Kazuyo Ichimori
World Health Organization, Geneva, Switzerland

 



Note: When adding presentations to your Itinerary, please click "Add Checked Selections to My Itinerary" on EACH page of your search results.